While the Federal Trade Commission lost out on claims AbbVie Inc. engaged in a pay-for-delay deal, it won the overall battle with a court ruling that the company filed sham infringement suits against Teva Pharmaceuticals USA Inc. and Perrigo Co. PLC to block generic competition for its transdermal testosterone replacement therapy AndroGel.
FTC Wins $448M Ruling Against AbbVie For Sham Litigation Rather Than Pay-For-Delay Deal
Court finds AbbVie used sham litigation to maintain its monopoly on AndroGel but denies FTC request for an injunction; it is the largest monetary award in a litigated FTC antitrust case.
